	US 12,227,771 B2
	Expression systems and methods of use thereof
David S. Bredt, La Jolla, CA (US); Weston Davini, San Diego, CA (US); Shenyan Gu, San Diego, CA (US); Jose Matta, San Diego, CA (US); and Min Lei O'Carroll, San Diego, CA (US)
Assigned to JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on May 15, 2020, as Appl. No. 16/875,550.
Claims priority of provisional application 62/849,653, filed on May 17, 2019.
Prior Publication US 2020/0362013 A1, Nov. 19, 2020
Int. Cl. C12N 5/00 (2006.01); C12N 5/071 (2010.01); C12N 9/10 (2006.01); C07K 14/705 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01)

CPC C12N 9/1029 (2013.01) [C12N 5/0602 (2013.01); C07K 14/70571 (2013.01); G01N 33/5008 (2013.01); G01N 33/68 (2013.01)]

6 Claims

1. An expression system for functional expression of α9α10 nAChR comprising a recombinant cell, wherein the recombinant cell is a cell transfected with one or more expression vectors, the one or more expression vectors comprising:

(i) a first nucleic acid encoding an α9 subunit of an α9α10 nicotinic acetylcholine receptor (nAChR), wherein the α9 subunit of the α9α10 nAChR comprises an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO:1;

(ii) a second nucleic acid encoding an α10 subunit of an α9α10 nAChR, wherein the α10 subunit of the α9α10 nAChR comprises an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO:2; and

(iii) a third nucleic acid encoding Choline O-acetyltransferase (CHAT), wherein the CHAT comprises an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO:3.